← back to search

Hamish S. Sutherland

University of Auckland · NZ
Area of research
Infectious Diseases · Molecular Biology
Research interest
Research interests include Chemistry, Bedaquiline, Lipophilicity, hERG, In vivo, and Stereochemistry.
h-index
citations
496
works
9
NIH funding
primary concept
email

Recent publications

Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of Mycobacterium tuberculosis. Structural correction of reported N-(6-(2-(dimethylamino)ethoxy)-5-fluoropyridin-3-yl)-2-(4-fluorophenyl)-5-(trifluoromethyl)pyrazolo[1,5-α]pyrimidin-7-amine
Tetrahedron Letters 2021cited by 14position: middledoi
Synthesis and structure-activity relationships for tetrahydroisoquinoline-based inhibitors of Mycobacterium tuberculosis
Bioorganic & Medicinal Chemistry 2020cited by 21position: middledoi
3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel
Bioorganic & Medicinal Chemistry 2019cited by 114position: firstdoi
Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline
Bioorganic & Medicinal Chemistry 2019cited by 52position: middledoi
Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology
Bioorganic & Medicinal Chemistry 2019cited by 37position: firstdoi
Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles
Bioorganic & Medicinal Chemistry 2018cited by 79position: firstdoi
6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis
ACS Medicinal Chemistry Letters 2017cited by 83position: middledoi
Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units
Bioorganic & Medicinal Chemistry Letters 2017cited by 58position: middledoi
Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6<i>S</i>)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine (PA-824)
Journal of Medicinal Chemistry 2015cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Brian D. Palmer · University of Auckland9 papers (2015–2021)William A. Denny · University of Otago9 papers (2015–2021)Scott G. Franzblau · University of Illinois Chicago9 papers (2015–2021) · 8 papers (2017–2021)Peter J. Choi · University of Auckland8 papers (2017–2021)Amy S.T. Tong · University of Auckland7 papers (2017–2020) · 7 papers (2017–2020) · 6 papers (2017–2020)Adrian Blaser · University of Auckland6 papers (2015–2019)Daniel Conole · University of Illinois Chicago5 papers (2017–2020)Guo‐Liang Lu · Shandong University2 papers (2020–2021) · 2 papers (2017–2017)Koen Andries · Texas A&M University2 papers (2017–2017) · 2 papers (2017–2017) · 2 papers (2017–2017)Andrew M. Thompson · University of Otago1 papers (2015–2015)Yuehong Wang · University of Illinois Chicago1 papers (2015–2015)Baojie Wan · University of Illinois Chicago1 papers (2015–2015)Anna C. Giddens · University of Auckland1 papers (2021–2021)Iveta Kmentová · University of Auckland1 papers (2015–2015)